BioPharmSignal logoBioPharmSignal

Biotech News

Candel Therapeutics to Present at TD Cowen’s 46th Annual Health Care Conference in Boston

Candel Therapeutics (CADL)Candel TherapeuticsConference / presentation

NEEDHAM, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that Paul Peter Tak, M.D., Ph.D.,

Related news

CADLCandel Therapeutics2026-07-29 12:05 EST

Candel Therapeutics to Present at Canaccord Genuity’s 46th Annual Growth Conference in Boston

CADLCandel Therapeutics2026-06-30 12:05 EST

Candel Therapeutics Announces Initiation of Global Pivotal Phase 3 AURORA Trial Evaluating Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors

CMPXCompass Therapeutics2026-07-17 14:42 EST

Compass Therapeutics Announces Tovecimig Data Accepted for an Oral Presentation at the ESMO Congress 2026

RVMDRevolution Medicines2026-06-24 23:31 EST

Revolution Medicines to Present Clinical Data from RAS(ON) Inhibitor Combination Trials in Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026

ZNTLZentalis2026-07-17 20:15 EST

Zentalis Pharmaceuticals to Present at the European Society for Medical Oncology (ESMO) Congress 2026

KURAKura Oncology2026-07-14 11:02 EST

Kura Oncology to Present First Long-Term Follow-Up Data Further Supporting Darlifarnib’s Potential to Enhance VEGFR-Targeted Therapy in Renal Cell Carcinoma at KCRS 2026

LYELLyell Immunopharma2026-06-25 12:00 EST

Lyell Immunopharma Announces Participation in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference

COGTCogent Biosciences2026-06-12 12:01 EST

Cogent Biosciences Announces Preclinical Data from Novel JAK2 V617F Inhibitor at the 2026 European Hematology Association (EHA) Congress

REGNRegeneron Pharmaceuticals2026-08-19 20:05 EST

Regeneron Announces Investor Conference Presentations

FATEFate Therapeutics2026-07-06 12:30 EST

Fate Therapeutics to Present Preliminary Clinical Data of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Sclerosis at the ISSCR 2026 Annual Meeting

View all latest news

Candel Therapeutics

Multimodal Cancer Immunotherapy Candel Therapeutics develops locally administered viral immunotherapies intended to induce immunogenic tumor-cell death and a systemic antitumor immune response. Aglatimagene Besadenovec Aglatimagene is an off-the-shelf, replication-defective adenovirus that delivers the HSV-thymidine-kinase gene into...

Recent company news

CADLCandel Therapeutics2026-08-13 12:05 EST

Candel Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

CADLCandel Therapeutics2026-08-03 20:05 EST

Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CADLCandel Therapeutics2026-08-03 12:05 EST

Candel Therapeutics to Present Extended Data from Phase 3 Results of Aglatimagene Besadenovec at ASTRO 2026

CADLCandel Therapeutics2026-07-29 12:05 EST

Candel Therapeutics to Present at Canaccord Genuity’s 46th Annual Growth Conference in Boston

CADLCandel Therapeutics2026-07-08 20:05 EST

Candel Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Stock data

Close
13.13 USD
Market cap
616.94M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States